Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Coeptis Therapeutics Holdings (COEP) has issued an announcement.
The Company’s Compensation Committee and Board of Directors have approved a significant incentive for CEO David Mehalick, awarding him options to acquire 2.4 million shares at the closing price on the date of approval, vested immediately with a 10-year term. Additionally, the firm announced the successful closure of their Series A Preferred sale in a recent press release.
See more data about COEP stock on TipRanks’ Stock Analysis page.